All In Biotech

Drug Trial Radar · NCT07918001

Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris

A Prospective, Observational, Phase IV, Open-Label, Multicenter, Single-Arm Study to Characterize the Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Fixed-Dose Combination Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Feb 25, 2026

Primary completion

Feb 28, 2027

Study completion May 10, 2027

Sponsor

Sponsor type
Industry
Collaborators
Glenmark Pharmaceuticals Ltd. India
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CLEAN ACNE Study is a prospective, observational, Phase IV, open-label, multicenter, single-arm study at 3-5 sites in Vietnam. It will describe the safety, tolerability, and clinical effectiveness of adapalene 0.1%/clindamycin 1% fixed-dose combination gel (Klenzit®-C) as used in routine clinical practice. Participants are Vietnamese patients aged 12 years and older with mild to moderate acne vulgaris. Patients whose treating physician has already prescribed Klenzit®-C as part of routine care will be invited to take part. The decision to prescribe is made independently of the study. About 360 participants will apply the gel once daily, preferably in the evening, for 12 weeks. Study visits take place at baseline and at Weeks 2, 4, 8, and 12. The main focus is safety and tolerability. This includes adverse events and local skin reactions such as redness, dryness, darkening of the skin, peeling, and itching. The study will also observe changes in inflammatory and non-inflammatory acne lesion counts. It will record the proportion of participants who reach treatment success on the Investigator Global Assessment (IGA) at Weeks 4, 8, and 12. An interim safety review will take place at Week 2, once about half of the participants have enrolled.

Conditions

  • Acne

Interventions

  • Klenzit®-C (Adapalene/Clindamycin Phosphate Gel)Drug

    Klenzit®-C (Adapalene/Clindamycin Phosphate Gel) Description: Topical gel containing adapalene 1 mg/g and clindamycin 10 mg/g, applied once daily to acne-affected areas of the face after cleansing and drying the skin. It is prescribed as part of routine clinical practice and not assigned by the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs and SAEs, and AEs Leading to DiscontinuationTime frame: From signing of informed consent up to Week 12 (Day 84)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Bach Mai Hospital

    Hanoi, Vietnam · Not yet recruiting

  • Ho Chi Minh City Hospital of Dermatology and Venereology

    Hanoi, Vietnam · Recruiting

  • Le Van Thinh Hospital

    Ho Chi Minh City, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.